Alpha-gal Allergen Inclusion Act

Bill Number: H.R. 1178
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Health
Status: Introduced
Latest Action: 2025-02-10: Referred to the House Committee on Energy and Commerce.
Last Updated: 2026-06-12T13:42:52Z

AI-Generated Summary

Purpose

The Alpha-gal Allergen Inclusion Act aims to protect individuals allergic to alpha-gal (a sugar molecule found in certain mammal products) by requiring its recognition and labeling as a major food allergen under federal law. This helps prevent severe allergic reactions, such as anaphylaxis, for those affected by alpha-gal syndrome, a condition often triggered by tick bites.

Key Provisions

Amendment to Definition: Adds "galactose-alpha-1,3-galactose" (commonly known as alpha-gal) as a new category of "major food allergen" in Section 201(qq) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Scope of Alpha-Gal:
Includes ingredients derived from non-catarrhine primate mammals (primates excluding humans, apes, and Old World monkeys) and red algae in the order Gigartinales.
Excludes mammal-derived ingredients where alpha-gal is not detectable above an established limit, such as those from genetically modified "alpha-gal-knockout" mammals.
Effective Date: The changes take effect 18 months after the bill's enactment, allowing time for compliance.

Significant Changes to Existing Law

Expands the FD&C Act's list of major food allergens, which previously included eight specific foods (e.g., milk, eggs, peanuts) plus any added by Congress. Alpha-gal becomes the first non-protein allergen explicitly defined, broadening protections beyond traditional protein-based allergens.
Introduces specific exclusions and detection thresholds, providing clarity on what qualifies as alpha-gal-containing ingredients, which was not previously addressed.

Potential Impacts

On Government Agencies: The Food and Drug Administration (FDA) will need to enforce new labeling requirements, update guidance, and possibly develop testing standards for alpha-gal detection, increasing regulatory oversight of food products.
On Citizens: Improves safety for the estimated 450,000+ Americans with alpha-gal syndrome by mandating clear labeling on foods containing alpha-gal, reducing accidental exposure risks. It may raise awareness of this emerging allergy.
On International Relations: Minimal direct impact, though it could influence U.S. food export/import standards if trading partners adopt similar labeling, potentially affecting global supply chains for mammal-derived products.
Broader Effects: Food prices might slightly increase due to reformulation or testing costs, but benefits public health by aligning U.S. law with growing scientific recognition of alpha-gal allergies.

Main Stakeholders Affected

Individuals with Alpha-Gal Syndrome: Primary beneficiaries, gaining better access to safe food options and reduced health risks.
Food Manufacturers and Processors: Must review and update ingredient sourcing, labeling, and production processes to comply, especially for products using mammal-derived items like gelatin or certain algae additives.
Healthcare Providers and Researchers: Supports allergy diagnosis and treatment by standardizing allergen information.
Consumers Without Allergies: Indirectly affected through potential changes in product availability or costs.
FDA and Regulatory Bodies: Responsible for implementation, enforcement, and education.

Notable Legal, Constitutional, or Political Implications

Legal: Strengthens consumer protection under the FD&C Act without creating new penalties; relies on existing FDA authority for allergen labeling violations (e.g., fines or product recalls). The 18-month delay aids smooth transition and avoids immediate litigation over compliance.
Constitutional: No apparent issues; aligns with Congress's power to regulate interstate commerce and public health under the Commerce Clause.
Political: Bipartisan support (introduced by a diverse group of representatives) highlights growing attention to food allergies as a public health issue. It sets a precedent for addressing novel allergens, potentially paving the way for future expansions of the major allergen list amid rising allergy rates.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Van Drew, Jefferson [R-NJ-2]

Cosponsors (43)

Rep. Murphy, Gregory F. [R-NC-3], Rep. Davis, Donald G. [D-NC-1], Rep. Balderson, Troy [R-OH-12], Rep. Carter, John R. [R-TX-31], Rep. LaMalfa, Doug [R-CA-1], Rep. Griffith, H. Morgan [R-VA-9], Rep. Magaziner, Seth [D-RI-2], Rep. Moore, Barry [R-AL-1], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Rulli, Michael A. [R-OH-6], Rep. Cline, Ben [R-VA-6], Rep. Wittman, Robert J. [R-VA-1], Rep. Cherfilus-McCormick, Sheila [D-FL-20], Rep. Smith, Christopher H. [R-NJ-4], Rep. Wilson, Joe [R-SC-2], Rep. Rose, John W. [R-TN-6], Del. Moylan, James C. [R-GU-At Large], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Hayes, Jahana [D-CT-5], Del. Radewagen, Aumua Amata Coleman [R-AS-At Large], Rep. Joyce, John [R-PA-13], Rep. McCormick, Richard [R-GA-7], Rep. Pou, Nellie [D-NJ-9], Rep. Kiggans, Jennifer A. [R-VA-2], Rep. Vindman, Eugene [D-VA-7], Rep. Subramanyam, Suhas [D-VA-10], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. LaLota, Nick [R-NY-1], Rep. Babin, Brian [R-TX-36], Rep. Schmidt, Derek [R-KS-2], Rep. Kelly, Trent [R-MS-1], Rep. Bice, Stephanie I. [R-OK-5], Rep. Fleischmann, Charles J. "Chuck" [R-TN-3], Rep. Keating, William R. [D-MA-9], Rep. Kean, Thomas H. [R-NJ-7], Rep. Davids, Sharice [D-KS-3], Rep. Miller, Carol D. [R-WV-1], Rep. Biggs, Sheri [R-SC-3], Rep. Pingree, Chellie [D-ME-1], Rep. Raskin, Jamie [D-MD-8], Rep. Balint, Becca [D-VT-At Large], Rep. McGuire, John J. [R-VA-5], Rep. Bonamici, Suzanne [D-OR-1]

Recent Actions

2025-02-10: Referred to the House Committee on Energy and Commerce.
2025-02-10: Introduced in House
2025-02-10: Introduced in House

Bill Versions

Alpha-gal Allergen Inclusion Act — issued 2025-02-10 — PDF (2 pages)